EBR Systems, Inc. engages in the development of implantable systems for wireless tissue stimulation. The company is headquartered in Sunnyvale, California. The company went IPO on 2021-11-24. The firm is developing the wireless stimulation endocardially cardiac resynchronization therapy (WiSE CRT) System an implantable cardiac pacing system able to provide stimulation to endocardial heart tissue for the correction of heart rhythm conditions without requiring the use of wires or leads. This investigational device delivers left-ventricle endocardial pacing for CRT without wires or leads. The WiSE CRT System developed a new approach to cardiac pacing, with the potential to transform CRT delivery and benefit patients who have not succeeded with conventional CRT. The company operates wholly owned subsidiaries in Australia, EBR Systems (AUST) Pty Ltd, and the United Kingdom, EBR Systems (UK) Limited, which conduct clinical trials and work on intellectual property development in their respective regions.
最新の財務諸表(Form-10K)によると、EBR Systems Incの総資産は$0で、純損失は$0です。
EBRCZの主要な財務比率は何ですか?
EBR Systems Incの流動比率は0、純利益率は0、1株当たり売上高は$0です。
EBR Systems Incの収益はセグメントまたは地域別にどのように分けられていますか?
EBR Systems Inc の最大収益セグメントは WiSE Cardiac Resynchronization Therapy System で、最新の利益発表における収益は 2,400,692 です。地域別に見ると、United States が EBR Systems Inc の主要市場であり、収益は 2,470,480 です。